Bruker Completes Acquisition of PhenomeX
03 Outubro 2023 - 8:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that it has
completed the acquisition of PhenomeX, a leading provider of
single-cell biology research tools, for $108 million in cash.
Bruker announced the agreement to acquire PhenomeX on August 17,
2023.
PhenomeX is a functional cell biology company that provides
single-cell biology research tools to deliver deep insights into
cellular function and new perspectives on phenomes and
genotype-to-phenotype linkages. PhenomeX key platforms include the
Beacon® line of Optofluidic systems, which enables researchers to
accelerate biologics product development by functional
characterization of tens of thousands of single cells in parallel,
while maintaining the cells in a healthy state for further genomic
and proteomic profiling, connecting phenotype with genotype and
other multiomic information. In addition, PhenomeX complements the
Beacon line of products with the IsoSpark and IsoLight systems for
highly multiplexed single-cell proteomic characterization.
“We are excited to welcome PhenomeX to Bruker,” commented Dr.
Mark R. Munch, President of the Bruker NANO Group. “PhenomeX’s
differentiated research tools are highly valued by customers in the
attractive growth markets of antibody development, cell line
development, cell and gene therapy, and many more. Also, PhenomeX’s
platforms are highly complementary to our existing cellular and
sub-cellular analysis tools including our high-performance
CellScape™ spatial biology platform.”
Bruker expects to right-size PhenomeX’s cost structure
immediately and expects the acquisition of PhenomeX to be slightly
dilutive to Bruker’s non-GAAP EPS in 2024 and 2025, and accretive
to Bruker’s non-GAAP EPS beginning in 2026. During its Q3 2023
earnings release, Bruker will provide more details on the expected
Q4 2023 effect from PhenomeX. Today, Bruker reconfirms its
medium-term financial outlook as issued at its Investor Day in June
2023.
As a result of the transaction closing, PhenomeX common stock
will no longer be listed for trading on the Nasdaq Global Market.
Also, PhenomeX will soon be changing its name.
About Bruker Corporation (Nasdaq: BRKR) Bruker is
enabling scientists to make breakthrough discoveries and develop
new applications that improve the quality of human life. Bruker’s
high-performance scientific instruments and high-value analytical
and diagnostic solutions enable scientists to explore life and
materials at molecular, cellular and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity and customer success in life science
molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains “forward-looking statements”
regarding Bruker’s acquisition of PhenomeX.
All statements, other than statements of historical facts,
including statements concerning Bruker’s and PhenomeX’s plans,
objectives, goals, beliefs, strategy and strategic objectives,
future events, business conditions, results of operations,
financial position, business outlook, business trends and other
information, may be forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,”
“should,” “strategy,” “target,” or “will” or the negatives of these
terms or variations of them or similar terminology. Readers are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties and are cautioned not to place undue reliance on
these forward-looking statements. Actual results may differ
materially from those currently anticipated due to a number of
risks and uncertainties. Risks and uncertainties include, but are
not limited to, Bruker’s ability to integrate PhenomeX and achieve
the expected synergies; risks relating to the potential diversion
of management’s attention from Bruker’s ongoing business
operations; the risk of stockholder litigation and any other legal
proceedings relating to the transaction, including resulting
expense; the risk that any announcements relating to the
transaction could have adverse effects on the market price of
Bruker’s common stock; the risk that the transaction and its
announcement could have an adverse effect on the ability of
PhenomeX to retain and hire key personnel and to maintain
relationships with customers, vendors, employees and other business
partners and on its operating results and business generally; and
the risk that Bruker’s financial results may not be consistent with
current guidance or that Bruker may not reliably predict the impact
of the acquisition on its financial results or guidance. For
further discussion of these and other risks and uncertainties, see
Bruker’s most recent Form 10-K and Form 10-Q filings with the SEC.
Except as required by law, Bruker does not undertake any duty to
update forward-looking statements to reflect events after the date
of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003528133/en/
Investor: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024